Perindopril (Tablets, Capsules) Instructions for Use

Instructions
Dosage forms

ATC Code

C09AA04 (Perindopril)

Active Substance

Perindopril (Rec.INN registered by WHO)

Clinical-Pharmacological Group

ACE inhibitor

Pharmacotherapeutic Group

Agents acting on the renin-angiotensin system; angiotensin-converting enzyme (ACE) inhibitors

Pharmacological Action

ACE inhibitor. It is a prodrug from which the active metabolite perindoprilat is formed in the body. It is believed that the mechanism of the antihypertensive action is associated with the competitive inhibition of ACE activity, which leads to a decrease in the rate of conversion of angiotensin I to angiotensin II, a potent vasoconstrictor substance. As a result of the decrease in the concentration of angiotensin II, a secondary increase in plasma renin activity occurs due to the elimination of the negative feedback during renin release and a direct decrease in aldosterone secretion. Due to its vasodilating action, it reduces total peripheral vascular resistance (afterload), pulmonary capillary wedge pressure (preload) and resistance in the pulmonary vessels; increases cardiac output and exercise tolerance.

The hypotensive effect develops within the first hour after taking perindopril, reaches a maximum in 4-8 hours and lasts for 24 hours.

In clinical studies with the use of perindopril (monotherapy or in combination with a diuretic), a significant reduction in the risk of recurrent stroke (both ischemic and hemorrhagic), as well as the risk of fatal or disabling strokes; major cardiovascular complications, including myocardial infarction, including fatal ones; dementia associated with stroke; serious deterioration of cognitive functions was shown. These therapeutic benefits were noted both in patients with arterial hypertension and in those with normal blood pressure, regardless of age, gender, presence or absence of diabetes and type of stroke.

It was shown that against the background of the use of perindopril tert-butylamine at a dose of 8 mg/day (equivalent to 10 mg of perindopril arginine) in patients with stable coronary artery disease, there is a significant reduction in the absolute risk of complications provided for by the main efficacy criterion (mortality from cardiovascular diseases, the frequency of non-fatal myocardial infarction and/or cardiac arrest with subsequent successful resuscitation) by 1.9%. In patients who had previously had a myocardial infarction or a coronary revascularization procedure, the absolute risk reduction was 2.2% compared to the placebo group.

Perindopril is used both as monotherapy and as fixed combinations with indapamide, with amlodipine.

Pharmacokinetics

After oral administration, Perindopril is rapidly absorbed from the gastrointestinal tract. C_max is reached in 1 hour. Bioavailability is 65-70%.

During metabolism, Perindopril is biotransformed to form an active metabolite – perindoprilat (about 20%) and 5 inactive compounds. C_max of perindoprilat in plasma is reached between 3 and 5 hours after administration. The binding of perindoprilat to plasma proteins is insignificant (less than 30%) and depends on the concentration of the active substance. V_d of free perindoprilat is close to 0.2 l/kg.

Does not accumulate. Repeated administration does not lead to accumulation and T_1/2 corresponds to the period of its activity.

When taken with food, the metabolism of perindopril slows down.

T_1/2 of perindopril is 1 hour.

Perindoprilat is excreted from the body by the kidneys; T_1/2 of its free fraction is 3-5 hours.

In elderly patients, as well as in renal and heart failure, the excretion of perindoprilat is slowed down.

Indications

Arterial hypertension.

Chronic heart failure.

Prevention of recurrent stroke (combined therapy with indapamide) in patients who have had a stroke or transient ischemic attack.

Stable coronary artery disease: reduction of the risk of cardiovascular complications in patients with stable coronary artery disease.

ICD codes

Open the list of ICD codes

ICD-10 code	Indication
G45	Transient cerebral ischemic attacks [TIAs] and related syndromes
I10	Essential [primary] hypertension
I20	Angina pectoris
I50.0	Congestive heart failure
I63	Cerebral infarction

ICD-11 code	Indication
8B10.Z	Transient ischemic attack, unspecified
8B11	Cerebral ischemic stroke
BA00.Z	Essential hypertension, unspecified
BA40.Z	Angina pectoris, unspecified
BD10	Congestive heart failure

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Administer once daily, preferably in the morning before a meal.

For arterial hypertension, initiate therapy at 2-4 mg once daily. Titrate to a maintenance dose of 4 mg once daily based on blood pressure response. The maximum dose is 8 mg once daily.

For chronic heart failure, start with 2 mg once daily under close medical supervision. Increase to a maintenance dose of 4 mg once daily after two weeks, provided the initial dose is well tolerated.

For secondary stroke prevention, use perindopril in a fixed-dose combination with indapamide. The recommended dose is perindopril arginine 5 mg plus indapamide 1.25 mg once daily. If necessary, after two weeks, increase to perindopril arginine 10 mg plus indapamide 2.5 mg once daily.

For stable coronary artery disease, the recommended dose is 4 mg once daily for two weeks, then increase to 8 mg once daily if tolerated.

In patients with renal impairment, adjust the dose based on creatinine clearance. For CrCl ≥60 mL/min, use up to 8 mg/day. For CrCl 30-60 mL/min, the maximum dose is 4 mg/day. For CrCl 15-30 mL/min, the maximum dose is 2 mg/day. For CrCl <15 mL/min (including dialysis), the maximum dose is 2 mg on dialysis days.

In elderly patients, initiate therapy at 2 mg once daily. Titrate cautiously, monitoring renal function and blood pressure.

For patients with dehydration or salt depletion, correct the condition prior to initiation. Start with a lower initial dose of 2 mg once daily.

Adverse Reactions

From the hematopoietic system eosinophilia, decrease in hemoglobin and hematocrit, thrombocytopenia, leukopenia/neutropenia, agranulocytosis, pancytopenia, hemolytic anemia in patients with congenital glucose-6-phosphate dehydrogenase deficiency.

From the metabolism hypoglycemia, hyperkalemia, reversible after drug withdrawal, hyponatremia.

From the nervous system paresthesia, headache, dizziness, vertigo, sleep disorders, mood lability, drowsiness, fainting, confusion.

From the senses visual disturbances, tinnitus.

From the cardiovascular system excessive decrease in blood pressure and associated symptoms, vasculitis, tachycardia, palpitation sensation, cardiac rhythm disorders, angina pectoris, myocardial infarction and stroke, possibly due to excessive decrease in blood pressure in high-risk patients.

From the respiratory system cough, shortness of breath, bronchospasm, eosinophilic pneumonia, rhinitis.

From the digestive system constipation, nausea, vomiting, abdominal pain, taste disturbance, dyspepsia, diarrhea, dryness of the oral mucosa, pancreatitis, hepatitis (cholestatic or cytolytic).

From the skin and subcutaneous tissue skin itching, rash, photosensitivity, pemphigus, increased sweating.

Allergic reactions angioedema, urticaria, erythema multiforme.

From the musculoskeletal system muscle cramps, arthralgia, myalgia.

From the urinary system renal failure, acute renal failure.

From the reproductive system erectile dysfunction.

General reactions asthenia, chest pain, peripheral edema, weakness, fever, falls.

From laboratory parameters increased activity of liver transaminases and bilirubin in blood serum, increased concentration of urea and creatinine in blood plasma.

Contraindications

History of angioedema, simultaneous use with aliskiren and aliskiren-containing drugs in patients with diabetes mellitus or impaired renal function (GFR <60 ml/min/1.73 m²), pregnancy, lactation, children and adolescents under 18 years of age, hypersensitivity to perindopril, hypersensitivity to other ACE inhibitors.

Use in Pregnancy and Lactation

Perindopril is contraindicated for use during pregnancy and during lactation (breastfeeding).

Use in Renal Impairment

In case of impaired renal function, correction of the dosage regimen is required depending on the creatinine clearance values.

Pediatric Use

Contraindicated in children.

Special Precautions

With caution, Perindopril should be used for bilateral renal artery stenosis or stenosis of the artery of a single kidney; renal failure; systemic connective tissue diseases; therapy with immunosuppressants, allopurinol, procainamide (risk of developing neutropenia, agranulocytosis); reduced circulating blood volume (taking diuretics, salt-restricted diet, vomiting, diarrhea); angina pectoris; cerebrovascular diseases; renovascular hypertension; diabetes mellitus; chronic heart failure of functional class IV according to the NYHA classification; simultaneously with potassium-sparing diuretics, potassium preparations, potassium-containing salt substitutes, with lithium preparations; with hyperkalemia; surgical intervention/general anesthesia; hemodialysis using high-flux membranes; desensitizing therapy; LDL apheresis; condition after kidney transplantation; aortic stenosis/mitral stenosis/hypertrophic obstructive cardiomyopathy; in patients of the Black race.

Cases of arterial hypotension, fainting, stroke, hyperkalemia and impaired renal function (including acute renal failure) have been reported in predisposed patients, especially with simultaneous use with drugs that affect the renin-angiotensin-aldosterone system. Therefore, dual blockade of the renin-angiotensin-aldosterone system as a result of the combination of an ACE inhibitor with an angiotensin II receptor antagonist or aliskiren is not recommended.

Before starting treatment with perindopril, it is recommended that all patients be examined for renal function.

During treatment with perindopril, renal function, the activity of liver enzymes in the blood should be regularly monitored, and peripheral blood tests should be performed (especially in patients with diffuse connective tissue diseases, in patients who are receiving immunosuppressive agents, allopurinol). Patients with sodium and fluid deficiency should correct water and electrolyte disturbances before starting treatment.

Drug Interactions

The risk of hyperkalemia increases with the simultaneous use of perindopril with other drugs that can cause hyperkalemia: aliskiren and aliskiren-containing drugs, potassium salts, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, NSAIDs, heparin, immunosuppressants such as cyclosporine or tacrolimus, trimethoprim.

With simultaneous use with aliskiren in patients with diabetes mellitus or impaired renal function (GFR <60 ml/min), the risk of hyperkalemia, deterioration of renal function and an increase in the frequency of cardiovascular morbidity and mortality increases (in patients of these groups, this combination is contraindicated).

Simultaneous use with aliskiren is not recommended in patients without diabetes mellitus or impaired renal function, as it may increase the risk of hyperkalemia, deterioration of renal function and an increase in the frequency of cardiovascular morbidity and mortality.

The literature has reported that in patients with established atherosclerotic disease, heart failure, or diabetes with target organ damage, simultaneous therapy with an ACE inhibitor and an angiotensin II receptor antagonist is associated with a higher incidence of hypotension, syncope, hyperkalemia, and deterioration of renal function (including acute renal failure) compared with the use of only one drug affecting the renin-angiotensin-aldosterone system. Dual blockade (for example, when combining an ACE inhibitor with an angiotensin II receptor antagonist) should be limited to individual cases with careful monitoring of renal function, potassium levels and blood pressure.

Simultaneous use with estramustine may lead to an increased risk of side effects such as angioedema.

With simultaneous use of lithium preparations and perindopril, a reversible increase in the concentration of lithium in the blood serum and associated toxic effects is possible (this combination is not recommended).

Simultaneous use with hypoglycemic drugs (insulin, oral hypoglycemic agents) requires special caution, since ACE inhibitors, including Perindopril, can enhance the hypoglycemic effect of these drugs up to the development of hypoglycemia. As a rule, this is observed in the first weeks of simultaneous therapy and in patients with impaired renal function.

Baclofen enhances the antihypertensive effect of perindopril; with simultaneous use, dose adjustment of the latter may be required.

In patients receiving diuretics, especially those that remove fluid and/or salts, at the beginning of therapy with perindopril, an excessive decrease in blood pressure may be observed, the risk of which can be reduced by discontinuing the diuretic, replenishing the loss of fluid or salts before starting therapy with perindopril, as well as by using perindopril in a low initial dose with its subsequent gradual increase.

In chronic heart failure, in case of using diuretics, Perindopril should be used in a low dose, possibly after reducing the dose of the simultaneously used potassium-sparing diuretic. In all cases, renal function (creatinine concentration) should be monitored in the first weeks of using ACE inhibitors.

Use of eplerenone or spironolactone in doses from 12.5 mg to 50 mg/day and ACE inhibitors (including perindopril) in low doses: in the therapy of heart failure of functional class II-IV according to the NYHA classification with left ventricular ejection fraction <40% and previously used ACE inhibitors and “loop” diuretics, there is a risk of developing hyperkalemia (with possible fatal outcome), especially in case of non-compliance with the recommendations regarding this combination. Before using this combination, it is necessary to make sure that there is no hyperkalemia and impaired renal function. It is recommended to regularly monitor the concentration of creatinine and potassium in the blood – weekly in the first month of treatment and monthly thereafter.

Simultaneous use of perindopril with NSAIDs (acetylsalicylic acid in a dose that has an anti-inflammatory effect, COX-2 inhibitors and non-selective NSAIDs) may lead to a decrease in the antihypertensive effect of ACE inhibitors. Simultaneous use of ACE inhibitors and NSAIDs can lead to deterioration of renal function, including the development of acute renal failure, and an increase in the potassium content in the blood serum, especially in patients with reduced renal function. Use this combination with caution in elderly patients. Patients should receive adequate amounts of fluid; it is recommended to carefully monitor renal function, both at the beginning and during treatment.

The hypotensive effect of perindopril may be enhanced with simultaneous use with other antihypertensive drugs, vasodilators, including short- and long-acting nitrates.

Simultaneous use of gliptins (linagliptin, saxagliptin, sitagliptin, vildagliptin) with ACE inhibitors (including perindopril) may increase the risk of developing angioedema due to the suppression of dipeptidyl peptidase IV activity by the gliptin.

Simultaneous use of perindopril with tricyclic antidepressants, antipsychotic drugs and general anesthetics may lead to an increase in the antihypertensive effect.

Sympathomimetics may weaken the antihypertensive effect of perindopril.

When using ACE inhibitors, including perindopril, in patients receiving intravenous gold preparation (sodium aurothiomalate), a symptom complex was described in which facial skin flushing, nausea, vomiting, and arterial hypotension were observed.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Perindopril [Aurobindo Pharma, Ltd. (India)]
Tablets 4 mg: 30 pcs.
Tablets 8 mg: 30 pcs.

Marketing Authorization Holder

Aurobindo Pharma, Ltd. (India)

Dosage Forms

	Perindopril	Tablets 4 mg: 30 pcs.
		Tablets 8 mg: 30 pcs.

Dosage Form, Packaging, and Composition

Tablets white or almost white, capsule-shaped, with an engraving “D” on one side and engravings “5” and “8” separated by a score on the other side.

	1 tab.
Perindopril erbumine	4 mg

Excipients : anhydrous lactose – 59.33 mg, anhydrous colloidal silicon dioxide – 0.27 mg, microcrystalline cellulose – 25.5 mg, magnesium stearate – 0.9 mg.

10 pcs. – blisters (3) complete with a desiccant (silica gel) – laminated foil bags (1) – cardboard packs.

Tablets white or almost white, round, biconvex, with an engraving “D” on one side and engravings “5” and “9” separated by a score on the other side.

	1 tab.
Perindopril erbumine	8 mg

Excipients : anhydrous lactose – 118.66 mg, anhydrous colloidal silicon dioxide – 0.54 mg, microcrystalline cellulose – 51 mg, magnesium stearate – 1.8 mg.

10 pcs. – blisters (3) complete with a desiccant (silica gel) – laminated foil bags (1) – cardboard packs.

Perindopril [TAD PHARMA GmbH (Germany)]
Tablets 2 mg: 14, 28, 30, 56, 60, 90, or 98 pcs.

Marketing Authorization Holder

TAD PHARMA GmbH (Germany)

Dosage Form

Perindopril

Tablets 2 mg: 14, 28, 30, 56, 60, 90, or 98 pcs.

Dosage Form, Packaging, and Composition

Tablets white or almost white, round, slightly biconvex, with a bevel.

	1 tab.
Perindopril erbumine	2 mg

Excipients: lactose monohydrate – 31.79 mg, microcrystalline cellulose – 11.25 mg, crospovidone – 4 mg, calcium chloride hexahydrate – 0.6 mg, magnesium stearate – 0.225 mg, colloidal silicon dioxide – 0.135 mg.

10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (6) – cardboard packs.
10 pcs. – contour cell packs (9) – cardboard packs.
14 pcs. – contour cell packs (1) – cardboard packs.
14 pcs. – contour cell packs (2) – cardboard packs.
14 pcs. – contour cell packs (4) – cardboard packs.
14 pcs. – contour cell packs (7) – cardboard packs.
30 pcs. – contour cell packs (1) – cardboard packs.
30 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – contour cell packs (3) – cardboard packs.

Perindopril [TAD PHARMA GmbH (Germany)]
Tablets 4 mg: 14, 28, 30, 56, 60, 90, or 98 pcs.

Marketing Authorization Holder

TAD PHARMA GmbH (Germany)

Dosage Form

Perindopril

Tablets 4 mg: 14, 28, 30, 56, 60, 90, or 98 pcs.

Dosage Form, Packaging, and Composition

Tablets white or almost white, oval, slightly biconvex, with a bevel and a score on one side.

	1 tab.
Perindopril erbumine	4 mg

Excipients: lactose monohydrate – 63.58 mg, microcrystalline cellulose – 22.5 mg, crospovidone – 8 mg, calcium chloride hexahydrate – 1.2 mg, magnesium stearate – 0.45 mg, colloidal silicon dioxide – 0.27 mg.

Perindopril [TAD PHARMA GmbH (Germany)]
Tablets 8 mg: 14, 28, 30, 56, 60, 90, or 98 pcs.

Marketing Authorization Holder

TAD PHARMA GmbH (Germany)

Dosage Form

Perindopril

Tablets 8 mg: 14, 28, 30, 56, 60, 90, or 98 pcs.

Dosage Form, Packaging, and Composition

Tablets white or almost white, round, slightly biconvex, with a bevel and a score on one side.

	1 tab.
Perindopril erbumine	8 mg

Excipients: lactose monohydrate – 127.16 mg, microcrystalline cellulose – 45 mg, crospovidone – 16 mg, calcium chloride hexahydrate – 2.4 mg, magnesium stearate – 0.9 mg, colloidal silicon dioxide – 0.54 mg.

Perindopril [Atoll LLC (Russia)]
Capsules 2 mg: 7, 10, 14, 20, 21, 28, 30, 35, 40, 42, 49, 50, 56, 60, 63, 70, 80, 90, 100, 120, 150, 180, 210, 240, 270, or 300 pcs.
Capsules 4 mg: 7, 10, 14, 20, 21, 28, 30, 35, 40, 42, 49, 50, 56, 60, 63, 70, 80, 90, 100, 120, 150, 180, 210, 240, 270, or 300 pcs.
Capsules 8 mg: 7, 10, 14, 20, 21, 28, 30, 35, 40, 42, 49, 50, 56, 60, 63, 70, 80, 90, 100, 120, 150, 180, 210, 240, 270, or 300 pcs.

Marketing Authorization Holder

Atoll LLC (Russia)

Manufactured By

Ozon, LLC (Russia)

Packaging and Quality Control Release

OZON, LLC (Russia)

Dosage Forms

	Perindopril	Capsules 2 mg: 7, 10, 14, 20, 21, 28, 30, 35, 40, 42, 49, 50, 56, 60, 63, 70, 80, 90, 100, 120, 150, 180, 210, 240, 270, or 300 pcs.
		Capsules 4 mg: 7, 10, 14, 20, 21, 28, 30, 35, 40, 42, 49, 50, 56, 60, 63, 70, 80, 90, 100, 120, 150, 180, 210, 240, 270, or 300 pcs.
		Capsules 8 mg: 7, 10, 14, 20, 21, 28, 30, 35, 40, 42, 49, 50, 56, 60, 63, 70, 80, 90, 100, 120, 150, 180, 210, 240, 270, or 300 pcs.

Dosage Form, Packaging, and Composition

Capsules hard, gelatin, size No. 2; capsule body dark blue, capsule cap grey-violet. Capsule contents – powder or a mixture of powder and granules, white or white with a yellowish tint. Compaction of the capsule contents conforming to the capsule shape is allowed, which disintegrates upon pressure.

	1 caps.
Perindopril erbumine	2 mg

Excipients: microcrystalline cellulose (MCC-112), potato starch, magnesium stearate.

Capsule shell composition brilliant black dye, black iron oxide dye, azorubine dye, brilliant blue dye, titanium dioxide, gelatin.

7 pcs. – contour cell packs (1-10) – cardboard packs.
10 pcs. – contour cell packs (1-10) – cardboard packs.
30 pcs. – contour cell packs (1-10) – cardboard packs.

Capsules hard, gelatin, size No. 2; capsule body dark blue, capsule cap blue. Capsule contents – powder or a mixture of powder and granules, white or white with a yellowish tint. Compaction of the capsule contents conforming to the capsule shape is allowed, which disintegrates upon pressure.

	1 caps.
Perindopril erbumine	4 mg

Excipients: microcrystalline cellulose (MCC-112), potato starch, magnesium stearate.

Capsule shell composition brilliant black dye, black iron oxide dye, azorubine dye, patent blue dye, titanium dioxide, gelatin.

7 pcs. – contour cell packs (1-10) – cardboard packs.
10 pcs. – contour cell packs (1-10) – cardboard packs.
30 pcs. – contour cell packs (1-10) – cardboard packs.

Capsules hard, gelatin, size No. 2; capsule body dark blue, capsule cap violet. Capsule contents – powder or a mixture of powder and granules, white or white with a yellowish tint. Compaction of the capsule contents conforming to the capsule shape is allowed, which disintegrates upon pressure.

	1 caps.
Perindopril erbumine	8 mg

Excipients: microcrystalline cellulose (MCC-112), potato starch, magnesium stearate.

Capsule shell composition brilliant black dye, black iron oxide dye, azorubine dye, patent blue dye, titanium dioxide, gelatin.

7 pcs. – contour cell packs (1-10) – cardboard packs.
10 pcs. – contour cell packs (1-10) – cardboard packs.
30 pcs. – contour cell packs (1-10) – cardboard packs.

Perindopril [Binnopharm Group LLC (Russia)]
Tablets 8 mg: from 7 to 270 pcs.

Marketing Authorization Holder

Binnopharm Group LLC (Russia)

Manufactured By

Aliym, JSC (Russia)

Dosage Form

Perindopril

Tablets 8 mg: from 7 to 270 pcs.

Dosage Form, Packaging, and Composition

Tablets white or almost white, round, flat-cylindrical in shape, with a bevel and a score.

	1 tab.
Perindopril erbumine	8 mg

Excipients: lactose, microcrystalline cellulose, type 112, colloidal silicon dioxide (aerosil), magnesium stearate.

From 7 to 30 pcs. – contour cell packs (from 1 to 9 pcs.) – cardboard packs.

Perindopril [Izvarino Pharma LLC (Russia)]
Film-coated tablets 2 mg: 10, 20, 30, 50, 60, or 90 pcs.

Marketing Authorization Holder

Izvarino Pharma LLC (Russia)

Dosage Form

Perindopril

Film-coated tablets 2 mg: 10, 20, 30, 50, 60, or 90 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets	1 tab.
Perindopril	2 mg

Perindopril [Izvarino Pharma LLC (Russia)]
Film-coated tablets 4 mg: 10, 20, 30, 50, 60, or 90 pcs.

Marketing Authorization Holder

Izvarino Pharma LLC (Russia)

Dosage Form

Perindopril

Film-coated tablets 4 mg: 10, 20, 30, 50, 60, or 90 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets	1 tab.
Perindopril	4 mg

Perindopril [Izvarino Pharma LLC (Russia)]
Film-coated tablets 8 mg: 10, 20, 30, 50, 60, or 90 pcs.

Marketing Authorization Holder

Izvarino Pharma LLC (Russia)

Dosage Form

Perindopril

Film-coated tablets 8 mg: 10, 20, 30, 50, 60, or 90 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets	1 tab.
Perindopril	8 mg

Perindopril [Irbit Chemical Pharmaceutical Plant, JSC (Russia)]
Tablets 4 mg: 30, 60, or 90 pcs.
Tablets 8 mg: 30, 60, or 90 pcs.

Marketing Authorization Holder

Irbit Chemical Pharmaceutical Plant, JSC (Russia)

Dosage Forms

	Perindopril	Tablets 4 mg: 30, 60, or 90 pcs.
		Tablets 8 mg: 30, 60, or 90 pcs.

Dosage Form, Packaging, and Composition

Tablets white or almost white, round, flat-cylindrical in shape, with a double-sided bevel.

	1 tab.
Perindopril erbumine	4 mg

Excipients: lactose monohydrate, microcrystalline cellulose 101, anhydrous colloidal silicon dioxide, magnesium stearate.

10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (6) – cardboard packs.
10 pcs. – contour cell packs (9) – cardboard packs.
30 pcs. – jars – cardboard packs.

Tablets white or almost white, round, flat-cylindrical in shape, with a double-sided bevel.

	1 tab.
Perindopril erbumine	8 mg

Excipients: lactose monohydrate, microcrystalline cellulose 101, anhydrous colloidal silicon dioxide, magnesium stearate.

Perindopril [Ozon, LLC (Russia)]
Tablets 4 mg: 10, 30, or 90 pcs.

Marketing Authorization Holder

Ozon, LLC (Russia)

Dosage Form

Perindopril

Tablets 4 mg: 10, 30, or 90 pcs.

Dosage Form, Packaging, and Composition

Tablets white or almost white, round, flat-cylindrical, with a score and a bevel.

	1 tab.
Perindopril erbumine	4 mg

Excipients: lactose (milk sugar) – 66.5 mg, microcrystalline cellulose (MCC-101 Premium) – 19 mg, corn starch – 7 mg, povidone K25 – 2.5 mg, magnesium stearate – 1 mg.

10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
30 pcs. – contour cell packs (1) – cardboard packs.
30 pcs. – contour cell packs (3) – cardboard packs.

Perindopril [Pranapharm, LLC (Russia)]
Tablets 2 mg: 10, 14, 20, 21, 28, 30, 40, 50, 60, 70, 80, 90, or 100 pcs.
Tablets 4 mg: 10, 14, 20, 21, 28, 30, 40, 50, 60, 70, 80, 90, or 100 pcs.
Tablets 8 mg: 10, 14, 20, 21, 28, 30, 40, 50, 60, 70, 80, 90, or 100 pcs.

Marketing Authorization Holder

Pranapharm, LLC (Russia)

Dosage Forms

	Perindopril	Tablets 2 mg: 10, 14, 20, 21, 28, 30, 40, 50, 60, 70, 80, 90, or 100 pcs.
		Tablets 4 mg: 10, 14, 20, 21, 28, 30, 40, 50, 60, 70, 80, 90, or 100 pcs.
		Tablets 8 mg: 10, 14, 20, 21, 28, 30, 40, 50, 60, 70, 80, 90, or 100 pcs.

Dosage Form, Packaging, and Composition

Tablets white or almost white, round, biconvex, without a score; slight marbling is allowed.

	1 tab.
Perindopril erbumine	2 mg

Excipients: lactose monohydrate – 88.94 mg, microcrystalline cellulose (type 102) – 18.56 mg, corn starch – 9.3 mg, magnesium stearate – 1.2 mg.

7 pcs. – contour cell packs (2) – cardboard packs.
7 pcs. – contour cell packs (3) – cardboard packs.
7 pcs. – contour cell packs (4) – cardboard packs.
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (4) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
10 pcs. – contour cell packs (6) – cardboard packs.
10 pcs. – contour cell packs (7) – cardboard packs.
10 pcs. – contour cell packs (8) – cardboard packs.
10 pcs. – contour cell packs (9) – cardboard packs.
10 pcs. – contour cell packs (10) – cardboard packs.

Tablets white or almost white, round, biconvex, with a score; slight marbling is allowed.

	1 tab.
Perindopril erbumine	4 mg

Excipients: lactose monohydrate – 120.45 mg, microcrystalline cellulose (type 102) – 20 mg, corn starch – 13.95 mg, magnesium stearate – 1.6 mg.

Tablets white or almost white, round, flat-cylindrical, with a score and a bevel; slight marbling is allowed.

	1 tab.
Perindopril erbumine	8 mg

Excipients: lactose monohydrate – 240.9 mg, microcrystalline cellulose (type 102) – 40 mg, corn starch – 27.9 mg, magnesium stearate – 3.2 mg.

Perindopril [Promomed Rus LLC (Russia)]
Tablets 2 mg: 10, 20, or 30 pcs.

Marketing Authorization Holder

Promomed Rus LLC (Russia)

Dosage Form

Perindopril

Tablets 2 mg: 10, 20, or 30 pcs.

Dosage Form, Packaging, and Composition

Tablets white or white with a yellowish or creamy tint, flat-cylindrical in shape with a bevel; slight marbling is allowed.

	1 tab.
Perindopril erbumine	2 mg

10 pcs. – contour cell packs (aluminum/PVC) (1) – cardboard packs.
10 pcs. – contour cell packs (aluminum/PVC) (2) – cardboard packs.
10 pcs. – contour cell packs (aluminum/PVC) (3) – cardboard packs.
20 pcs. – polymer jars with a first-opening ring (1) – cardboard packs.
30 pcs. – polymer jars with a first-opening ring (1) – cardboard packs.
20 pcs. – jars (1) of light-protective glass – cardboard packs.
30 pcs. – jars (1) of light-protective glass – cardboard packs.

Perindopril [Promomed Rus LLC (Russia)]
Tablets 4 mg: 10, 20, or 30 pcs.

Marketing Authorization Holder

Promomed Rus LLC (Russia)

Dosage Form

Perindopril

Tablets 4 mg: 10, 20, or 30 pcs.

Dosage Form, Packaging, and Composition

Tablets white or white with a yellowish or creamy tint, flat-cylindrical in shape with a bevel; slight marbling is allowed.

	1 tab.
Perindopril erbumine	4 mg

Perindopril [Promomed Rus LLC (Russia)]
Tablets 8 mg: 10, 20, or 30 pcs.

Marketing Authorization Holder

Promomed Rus LLC (Russia)

Dosage Form

Perindopril

Tablets 8 mg: 10, 20, or 30 pcs.

Dosage Form, Packaging, and Composition

Tablets white or white with a yellowish or creamy tint, flat-cylindrical in shape with a bevel; slight marbling is allowed.

	1 tab.
Perindopril erbumine	8 mg

Perindopril Avexima [Avexima JSC (Russia)]
Tablets 4 mg: 30, 60, or 90 pcs.

Marketing Authorization Holder

Avexima JSC (Russia)

Manufactured By

Irbit Chemical Pharmaceutical Plant, JSC (Russia)

Avexima Siberia LLC (Russia)

Dosage Form

Perindopril Avexima

Tablets 4 mg: 30, 60, or 90 pcs.

Dosage Form, Packaging, and Composition

Tablets white or almost white, round, flat-cylindrical in shape, with a bevel on both sides.

	1 tab.
Perindopril erbumine	4 mg

Excipients: lactose monohydrate – 62.78 mg, microcrystalline cellulose – 22.5 mg, colloidal silicon dioxide – 0.27 mg, magnesium stearate – 0.45 mg.

10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (6) – cardboard packs.
10 pcs. – contour cell packs (9) – cardboard packs.
30 pcs. – polyethylene jars (1) – cardboard packs.

Perindopril Canon [Canonpharma Production, CJS (Russia)]
Film-coated tablets 5 mg: 7, 10, 14, 20, 28, 30, 56, 60, or 90 pcs.
Film-coated tablets 10 mg: 7, 10, 14, 20, 28, 30, 56, 60, or 90 pcs.

Marketing Authorization Holder

Canonpharma Production, CJS (Russia)

Dosage Forms

	Perindopril Canon	Film-coated tablets 5 mg: 7, 10, 14, 20, 28, 30, 56, 60, or 90 pcs.
		Film-coated tablets 10 mg: 7, 10, 14, 20, 28, 30, 56, 60, or 90 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets green, heart-shaped with a score on both sides; white or almost white on the cross-section.

	1 tab.
Perindopril arginine	5 mg

Excipients: hydrophobic colloidal silicon dioxide, copovidone, magnesium stearate, maltodextrin, microcrystalline cellulose (type 302).

Film coating composition hypromellose (hydroxypropyl methylcellulose), macrogol 6000 (polyethylene glycol), talc, titanium dioxide, brilliant blue dye, tartrazine dye, yellow iron oxide.

7 pcs. – contour cell pack (1, 2, 4 or 8) – cardboard packs with an insert.
10 pcs. – contour cell pack (1, 2, 3 or 6) – cardboard packs with an insert.
14 pcs. – contour cell pack (1, 2 or 4) – cardboard packs with an insert.
30 pcs. – contour cell pack (1 or 2) – cardboard packs with an insert.
60 pcs. – polymer jars (1) – cardboard packs with an insert.
90 pcs. – polymer jars (1) – cardboard packs with an insert.

Film-coated tablets green, round, biconvex; white or almost white on the cross-section.

	1 tab.
Perindopril arginine	10 mg

Excipients: hydrophobic colloidal silicon dioxide, copovidone, magnesium stearate, maltodextrin, microcrystalline cellulose (type 302).

Film coating composition hypromellose (hydroxypropyl methylcellulose), macrogol 6000 (polyethylene glycol), talc, titanium dioxide, brilliant blue dye, tartrazine dye, yellow iron oxide.

Perindopril Medisorb [Medisorb, JSC (Russia)]
Tablets 4 mg
Tablets 8 mg

Marketing Authorization Holder

Medisorb, JSC (Russia)

Dosage Forms

	Perindopril Medisorb	Tablets 4 mg
		Tablets 8 mg

Dosage Form, Packaging, and Composition

Tablets

	1 tab.
Perindopril erbumine	4 mg

10 pcs. – contour cell packs (3 pcs.) – cardboard packs (30 pcs.) – By prescription

Tablets

	1 tab.
Perindopril erbumine	8 mg

10 pcs. – contour cell packs (3 pcs.) – cardboard packs (30 pcs.) – By prescription

Perindopril Pharmasyntez [Pharmasintez-Tyumen, LLC (Russia)]
Tablets 2 mg: 10, 14, 20, 30, 60, or 90 pcs.
Tablets 4 mg: 10, 14, 20, 30, 60, or 90 pcs.

Marketing Authorization Holder

Pharmasintez-Tyumen, LLC (Russia)

Dosage Forms

	Perindopril Pharmasyntez	Tablets 2 mg: 10, 14, 20, 30, 60, or 90 pcs.
		Tablets 4 mg: 10, 14, 20, 30, 60, or 90 pcs.

Dosage Form, Packaging, and Composition

Tablets from white to almost white, round, flat-cylindrical, with a bevel.

	1 tab.
Perindopril erbumine	2 mg

Excipients: lactose monohydrate – 52.4 mg, microcrystalline cellulose type 102 – 35.03 mg, magnesium stearate – 0.35 mg, colloidal silicon dioxide – 0.22 mg.

10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (6) – cardboard packs.
10 pcs. – contour cell packs (9) – cardboard packs.
14 pcs. – jars (1) with first-opening control – cardboard packs.
30 pcs. – jars (1) with first-opening control – cardboard packs.
60 pcs. – jars (1) with first-opening control – cardboard packs.
90 pcs. – jars (1) with first-opening control – cardboard packs.

Tablets from white to almost white, round, flat-cylindrical, with a bevel.

	1 tab.
Perindopril erbumine	4 mg

Excipients: lactose monohydrate – 52.4 mg, microcrystalline cellulose type 102 – 35.03 mg, magnesium stearate – 0.35 mg, colloidal silicon dioxide – 0.22 mg.

Perindopril Renewal [Obnovlenie Pfc, JSC (Russia)]
Tablets 2 mg: 28, 30, 56, 60, or 90 pcs.
Tablets 4 mg: 28, 30, 56, 60, or 90 pcs.
Tablets 8 mg: 28, 30, 56, 60, or 90 pcs.

Marketing Authorization Holder

Obnovlenie Pfc, JSC (Russia)

Dosage Forms

	Perindopril Renewal	Tablets 2 mg: 28, 30, 56, 60, or 90 pcs.
		Tablets 4 mg: 28, 30, 56, 60, or 90 pcs.
		Tablets 8 mg: 28, 30, 56, 60, or 90 pcs.

Dosage Form, Packaging, and Composition

Tablets round, biconvex, white or almost white; marbling is allowed.

	1 tab.
Perindopril erbumine	2 mg

Excipients: lactose monohydrate, microcrystalline cellulose, corn starch, croscarmellose sodium, magnesium stearate.

10 pcs. – contour cell pack (3) – cardboard packs.
10 pcs. – contour cell pack (6) – cardboard packs.
10 pcs. – contour cell pack (9) – cardboard packs.
14 pcs. – contour cell pack (2) – cardboard packs.
14 pcs. – contour cell pack (4) – cardboard packs.
15 pcs. – contour cell pack (2) – cardboard packs.
15 pcs. – contour cell pack (4) – cardboard packs.
15 pcs. – contour cell pack (6) – cardboard packs.

Tablets round, biconvex, white or almost white with a score; marbling is allowed. The tablet can be divided into equal doses.

	1 tab.
Perindopril erbumine	4 mg

Excipients: lactose monohydrate, microcrystalline cellulose, corn starch, croscarmellose sodium, magnesium stearate.

Tablets round, flat-cylindrical, white or almost white with a bevel and a score; marbling is allowed. The tablet can be divided into equal doses.

	1 tab.
Perindopril erbumine	8 mg

Excipients: lactose monohydrate, microcrystalline cellulose, corn starch, croscarmellose sodium, magnesium stearate.

Perindopril solopharm [Grotex, LLC (Russia)]
Film-coated tablets 5 mg: 7, 10, 14, 20, 21, 28, 30, 35, 40, 42, 49, 50, 56, 60, 63, 70, 80, 90, or 100 pcs.
Film-coated tablets 10 mg: 7, 10, 14, 20, 21, 28, 30, 35, 40, 42, 49, 50, 56, 60, 63, 70, 80, 90, or 100 pcs.

Marketing Authorization Holder

Grotex, LLC (Russia)

Dosage Forms

	Perindopril solopharm	Film-coated tablets 5 mg: 7, 10, 14, 20, 21, 28, 30, 35, 40, 42, 49, 50, 56, 60, 63, 70, 80, 90, or 100 pcs.
		Film-coated tablets 10 mg: 7, 10, 14, 20, 21, 28, 30, 35, 40, 42, 49, 50, 56, 60, 63, 70, 80, 90, or 100 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets oval, biconvex, coated with a white or almost white film coating, with a dividing score on one side.

	1 tab.
Perindopril arginine	5 mg,
(equivalent to perindopril content)	3.395 mg

Excipients: lactose monohydrate, maltodextrin, sodium starch glycolate, magnesium stearate, hydrophobic colloidal silicon dioxide.

Film coating polyvinyl alcohol, talc, titanium dioxide, glyceryl monocaprylocaprate, sodium lauryl sulfate.

7 pcs. – contour cell pack (1) – cardboard packs.
7 pcs. – contour cell pack (2) – cardboard packs.
7 pcs. – contour cell pack (3) – cardboard packs.
7 pcs. – contour cell pack (4) – cardboard packs.
7 pcs. – contour cell pack (5) – cardboard packs.
7 pcs. – contour cell pack (6) – cardboard packs.
7 pcs. – contour cell pack (7) – cardboard packs.
7 pcs. – contour cell pack (8) – cardboard packs.
7 pcs. – contour cell pack (9) – cardboard packs.
7 pcs. – contour cell pack (10) – cardboard packs.
10 pcs. – contour cell pack (1) – cardboard packs.
10 pcs. – contour cell pack (2) – cardboard packs.
10 pcs. – contour cell pack (3) – cardboard packs.
10 pcs. – contour cell pack (4) – cardboard packs.
10 pcs. – contour cell pack (5) – cardboard packs.
10 pcs. – contour cell pack (6) – cardboard packs.
10 pcs. – contour cell pack (7) – cardboard packs.
10 pcs. – contour cell pack (8) – cardboard packs.
10 pcs. – contour cell pack (9) – cardboard packs.
10 pcs. – contour cell pack (10) – cardboard packs.
14 pcs. – polypropylene bottles (1) – cardboard packs.
20 pcs. – polypropylene bottles (1) – cardboard packs.
30 pcs. – polypropylene bottles (1) – cardboard packs.
60 pcs. – polypropylene bottles (1) – cardboard packs.
70 pcs. – polypropylene bottles (1) – cardboard packs.
80 pcs. – polypropylene bottles (1) – cardboard packs.
90 pcs. – polypropylene bottles (1) – cardboard packs.

Film-coated tablets oval, biconvex, film-coated white or almost white.

	1 tab.
Perindopril arginine	10 mg,
(equivalent to perindopril content)	6.79 mg

Excipients: lactose monohydrate, maltodextrin, sodium starch glycolate, magnesium stearate, colloidal hydrophobic silicon dioxide.

Film coating: polyvinyl alcohol, talc, titanium dioxide, glyceryl monocaprylocaprate, sodium lauryl sulfate.

7 pcs. – contour cell packaging (1) – cardboard packs.
7 pcs. – contour cell packaging (2) – cardboard packs.
7 pcs. – contour cell packaging (3) – cardboard packs.
7 pcs. – contour cell packaging (4) – cardboard packs.
7 pcs. – contour cell packaging (5) – cardboard packs.
7 pcs. – contour cell packaging (6) – cardboard packs.
7 pcs. – contour cell packaging (7) – cardboard packs.
7 pcs. – contour cell packaging (8) – cardboard packs.
7 pcs. – contour cell packaging (9) – cardboard packs.
7 pcs. – contour cell packaging (10) – cardboard packs.
10 pcs. – contour cell packaging (1) – cardboard packs.
10 pcs. – contour cell packaging (2) – cardboard packs.
10 pcs. – contour cell packaging (3) – cardboard packs.
10 pcs. – contour cell packaging (4) – cardboard packs.
10 pcs. – contour cell packaging (5) – cardboard packs.
10 pcs. – contour cell packaging (6) – cardboard packs.
10 pcs. – contour cell packaging (7) – cardboard packs.
10 pcs. – contour cell packaging (8) – cardboard packs.
10 pcs. – contour cell packaging (9) – cardboard packs.
10 pcs. – contour cell packaging (10) – cardboard packs.
14 pcs. – polypropylene bottles (1) – cardboard packs.
20 pcs. – polypropylene bottles (1) – cardboard packs.
30 pcs. – polypropylene bottles (1) – cardboard packs.
60 pcs. – polypropylene bottles (1) – cardboard packs.
70 pcs. – polypropylene bottles (1) – cardboard packs.
80 pcs. – polypropylene bottles (1) – cardboard packs.
90 pcs. – polypropylene bottles (1) – cardboard packs.

Perindopril Velpharm [Velpharm-M, LLC (Russia)]
Film-coated tablets 2.5 mg
Film-coated tablets 5 mg
Film-coated tablets 10 mg

Marketing Authorization Holder

Velpharm-M, LLC (Russia)

Dosage Forms

	Perindopril Velpharm	Film-coated tablets 2.5 mg
		Film-coated tablets 5 mg
		Film-coated tablets 10 mg

Dosage Form, Packaging, and Composition

Film-coated tablets

	1 tab.
Perindopril arginine	2.5 mg

10 pcs. – jars – cardboard packs (10 pcs.) – Prescription only
10 pcs. – contour cell packaging – cardboard packs (10 pcs.) – Prescription only
10 pcs. – contour cell packaging (10 pcs.) – cardboard packs (100 pcs.) – Prescription only
10 pcs. – contour cell packaging (2 pcs.) – cardboard packs (20 pcs.) – Prescription only
10 pcs. – contour cell packaging (3 pcs.) – cardboard packs (30 pcs.) – Prescription only
10 pcs. – contour cell packaging (4 pcs.) – cardboard packs (40 pcs.) – Prescription only
10 pcs. – contour cell packaging (5 pcs.) – cardboard packs (50 pcs.) – Prescription only
10 pcs. – contour cell packaging (6 pcs.) – cardboard packs (60 pcs.) – Prescription only
10 pcs. – contour cell packaging (7 pcs.) – cardboard packs (70 pcs.) – Prescription only
10 pcs. – contour cell packaging (8 pcs.) – cardboard packs (80 pcs.) – Prescription only
10 pcs. – contour cell packaging (9 pcs.) – cardboard packs (90 pcs.) – Prescription only
100 pcs. – jars – cardboard packs (100 pcs.) – Prescription only
14 pcs. – jars – cardboard packs (14 pcs.) – Prescription only
14 pcs. – contour cell packaging – cardboard packs (14 pcs.) – Prescription only
15 pcs. – contour cell packaging – cardboard packs (15 pcs.) – Prescription only
20 pcs. – jars – cardboard packs (20 pcs.) – Prescription only
21 pcs. – jars – cardboard packs (21 pcs.) – Prescription only
28 pcs. – jars – cardboard packs (28 pcs.) – Prescription only
29 pcs. – jars – cardboard packs (29 pcs.) – Prescription only
30 pcs. – jars – cardboard packs (30 pcs.) – Prescription only
40 pcs. – jars – cardboard packs (40 pcs.) – Prescription only
50 pcs. – jars – cardboard packs (50 pcs.) – Prescription only
60 pcs. – jars – cardboard packs (60 pcs.) – Prescription only
7 pcs. – contour cell packaging – cardboard packs (7 pcs.) – Prescription only
7 pcs. – contour cell packaging (10 pcs.) – cardboard packs (70 pcs.) – Prescription only
7 pcs. – contour cell packaging (2 pcs.) – cardboard packs (14 pcs.) – Prescription only
7 pcs. – contour cell packaging (3 pcs.) – cardboard packs (21 pcs.) – Prescription only
7 pcs. – contour cell packaging (4 pcs.) – cardboard packs (28 pcs.) – Prescription only
7 pcs. – contour cell packaging (5 pcs.) – cardboard packs (35 pcs.) – Prescription only
7 pcs. – contour cell packaging (6 pcs.) – cardboard packs (42 pcs.) – Prescription only
7 pcs. – contour cell packaging (7 pcs.) – cardboard packs (49 pcs.) – Prescription only
7 pcs. – contour cell packaging (8 pcs.) – cardboard packs (56 pcs.) – Prescription only
7 pcs. – contour cell packaging (9 pcs.) – cardboard packs (63 pcs.) – Prescription only
90 pcs. – jars – cardboard packs (90 pcs.) – Prescription only

Film-coated tablets

	1 tab.
Perindopril arginine	5 mg

Film-coated tablets

	1 tab.
Perindopril arginine	10 mg

Perindopril-Alium [Aliym, JSC (Russia)]
Tablets 4 mg: 7, 10, 14, 15, 20, 21, 28, 30, 35, 40, 42, 45, 50, 56, 60, 70, 75, 84, 90, 120, 150 or 180 pcs.

Marketing Authorization Holder

Aliym, JSC (Russia)

Dosage Form

Perindopril-Alium

Tablets 4 mg: 7, 10, 14, 15, 20, 21, 28, 30, 35, 40, 42, 45, 50, 56, 60, 70, 75, 84, 90, 120, 150 or 180 pcs.

Dosage Form, Packaging, and Composition

Tablets white or almost white, biconvex, oblong with rounded ends, with a score line.

	1 tab.
Perindopril erbumine	4 mg

Excipients: anhydrous lactose, microcrystalline cellulose type 112, colloidal silicon dioxide (aerosil), magnesium stearate.

7 pcs. – contour cell packaging (1) – cardboard packs.
7 pcs. – contour cell packaging (2) – cardboard packs.
7 pcs. – contour cell packaging (3) – cardboard packs.
7 pcs. – contour cell packaging (4) – cardboard packs.
7 pcs. – contour cell packaging (5) – cardboard packs.
7 pcs. – contour cell packaging (6) – cardboard packs.
10 pcs. – contour cell packaging (1) – cardboard packs.
10 pcs. – contour cell packaging (2) – cardboard packs.
10 pcs. – contour cell packaging (3) – cardboard packs.
10 pcs. – contour cell packaging (4) – cardboard packs.
10 pcs. – contour cell packaging (5) – cardboard packs.
10 pcs. – contour cell packaging (6) – cardboard packs.
14 pcs. – contour cell packaging (1) – cardboard packs.
14 pcs. – contour cell packaging (2) – cardboard packs.
14 pcs. – contour cell packaging (3) – cardboard packs.
14 pcs. – contour cell packaging (4) – cardboard packs.
14 pcs. – contour cell packaging (5) – cardboard packs.
14 pcs. – contour cell packaging (6) – cardboard packs.
15 pcs. – contour cell packaging (1) – cardboard packs.
15 pcs. – contour cell packaging (2) – cardboard packs.
15 pcs. – contour cell packaging (3) – cardboard packs.
15 pcs. – contour cell packaging (4) – cardboard packs.
15 pcs. – contour cell packaging (5) – cardboard packs.
15 pcs. – contour cell packaging (6) – cardboard packs.
30 pcs. – contour cell packaging (1) – cardboard packs.
30 pcs. – contour cell packaging (2) – cardboard packs.
30 pcs. – contour cell packaging (3) – cardboard packs.
30 pcs. – contour cell packaging (4) – cardboard packs.
30 pcs. – contour cell packaging (5) – cardboard packs.
30 pcs. – contour cell packaging (6) – cardboard packs.

Perindopril-Alsi [Alsi Pharma, JSC (Russia)]
Tablets 4 mg
Tablets 8 mg

Marketing Authorization Holder

Alsi Pharma, JSC (Russia)

Dosage Forms

	Perindopril-Alsi	Tablets 4 mg
		Tablets 8 mg

Dosage Form, Packaging, and Composition

Tablets

	1 tab.
Perindopril erbumine	4 mg

Tablets

	1 tab.
Perindopril erbumine	8 mg

Perindopril-Tad [TAD PHARMA GmbH (Germany)]
Tablets 4 mg
Tablets 8 mg

Marketing Authorization Holder

TAD PHARMA GmbH (Germany)

Manufactured By

Krka-Rus, LLC (Russia)

Dosage Forms

	Perindopril-Tad	Tablets 4 mg
		Tablets 8 mg

Dosage Form, Packaging, and Composition

Tablets

	1 tab.
Perindopril erbumine	4 mg

10 pcs. – contour cell packaging (3 pcs.) – cardboard packs (30 pcs.) – Prescription only
10 pcs. – contour cell packaging (6 pcs.) – cardboard packs (60 pcs.) – Prescription only
10 pcs. – contour cell packaging (9 pcs.) – cardboard packs (90 pcs.) – Prescription only
14 pcs. – contour cell packaging – cardboard packs (14 pcs.) – Prescription only
14 pcs. – contour cell packaging (2 pcs.) – cardboard packs (28 pcs.) – Prescription only
14 pcs. – contour cell packaging (4 pcs.) – cardboard packs (56 pcs.) – Prescription only
14 pcs. – contour cell packaging (7 pcs.) – cardboard packs (98 pcs.) – Prescription only
30 pcs. – contour cell packaging – cardboard packs (30 pcs.) – Prescription only
30 pcs. – contour cell packaging (2 pcs.) – cardboard packs (60 pcs.) – Prescription only
30 pcs. – contour cell packaging (3 pcs.) – cardboard packs (90 pcs.) – Prescription only

Tablets

	1 tab.
Perindopril erbumine	8 mg

Perindopril-Teva [Teva Pharmaceutical Industries, Ltd. (Israel)]
Film-coated tablets, 2.5 mg: 30 pcs.

Marketing Authorization Holder

Teva Pharmaceutical Industries, Ltd. (Israel)

Manufactured By

Teva Pharmaceutical Works, Private Limited Company (Hungary)

Dosage Form

Perindopril-Teva

Film-coated tablets, 2.5 mg: 30 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets white, round, biconvex, with an engraving “T” on one side; on cross-section – a core of white or almost white color.

	1 tab.
Perindopril tosilate	2.5 mg,
Equivalent to perindopril	1.6975 mg

Excipients: lactose monohydrate – 35.981 mg, corn starch – 1.35 mg, sodium bicarbonate – 0.793 mg, pregelatinized corn starch – 3.6 mg, povidone K30 – 0.9 mg, magnesium stearate – 0.45 mg, partially hydrolyzed polyvinyl alcohol – 0.9 mg, titanium dioxide (E171) – 0.5625 mg, macrogol 3350 (polyethylene glycol 3350) – 0.4545 mg, talc – 0.333 mg.

30 pcs. – polypropylene containers (1) – cardboard packs with first-opening control.

Perindopril-Teva [Teva Pharmaceutical Industries, Ltd. (Israel)]
Film-coated tablets, 5 mg: 30 pcs.

Marketing Authorization Holder

Teva Pharmaceutical Industries, Ltd. (Israel)

Manufactured By

Teva Pharmaceutical Works, Private Limited Company (Hungary)

Dosage Form

Perindopril-Teva

Film-coated tablets, 5 mg: 30 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets light green in color, capsule-shaped, biconvex; with a decorative score along the edge of the tablet on both sides; on one side – an engraving “T”; on the cross-section – a white or almost white core.

	1 tab.
Perindopril tosilate	5 mg,
Equivalent to perindopril	3.395 mg

Excipients: lactose monohydrate – 71.962 mg, corn starch – 2.7 mg, sodium bicarbonate – 1.586 mg, pregelatinized corn starch – 7.2 mg, povidone K30 – 1.8 mg, magnesium stearate – 0.9 mg, partially hydrolyzed polyvinyl alcohol – 1.8 mg, titanium dioxide (E171) – 1.0935 mg, macrogol 3350 (polyethylene glycol 3350) – 0.909 mg, talc – 0.666 mg, indigo carmine aluminum lake (E132) – 0.0144 mg, brilliant blue dye aluminum lake (E133) – 0.0081 mg, iron oxide yellow dye (E172) – 0.0045 mg, quinoline yellow dye aluminum lake (E104) – 0.0045 mg.

30 pcs. – polypropylene containers (1) – cardboard packs with first-opening control.

Perindopril-Teva [Teva Pharmaceutical Industries, Ltd. (Israel)]
Film-coated tablets, 10 mg: 30 pcs.

Marketing Authorization Holder

Teva Pharmaceutical Industries, Ltd. (Israel)

Manufactured By

Teva Pharmaceutical Works, Private Limited Company (Hungary)

Dosage Form

Perindopril-Teva

Film-coated tablets, 10 mg: 30 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets green in color, round, biconvex, on one side – an engraving “10”, on the other – “T”; on the cross-section – a white or almost white core.

	1 tab.
Perindopril tosilate	10 mg,
Equivalent to perindopril	6.79 mg

Excipients: lactose monohydrate – 143.924 mg, corn starch – 5.4 mg, sodium bicarbonate – 3.172 mg, pregelatinized corn starch – 14.4 mg, povidone K30 – 3.6 mg, magnesium stearate – 1.8 mg, partially hydrolyzed polyvinyl alcohol – 3.6 mg, titanium dioxide (E171) – 2.133 mg, macrogol 3350 (polyethylene glycol 3350) – 1.818 mg, talc – 1.332 mg, indigo carmine aluminum lake (E132) – 0.0495 mg, brilliant blue dye aluminum lake (E133) – 0.0315 mg, iron oxide yellow dye (E172) – 0.018 mg, quinoline yellow dye aluminum lake (E104) – 0.018 mg.

30 pcs. – polypropylene containers (1) – cardboard packs with first-opening control.

Perindopril-Vertex [Vertex, JSC (Russia)]
Tablets 4 mg: 10 or 30 pcs.

Marketing Authorization Holder

Vertex, JSC (Russia)

Dosage Form

Perindopril-Vertex

Tablets 4 mg: 10 or 30 pcs.

Dosage Form, Packaging, and Composition

Tablets white or almost white, round, flat-cylindrical, with a bevel.

	1 tab.
Perindopril erbumine	4 mg

Excipients: lactose monohydrate, microcrystalline cellulose, heavy magnesium oxide, croscarmellose sodium, magnesium stearate.

10 pcs. – contour cell blisters (1) – cardboard packs.
10 pcs. – contour cell blisters (3) – cardboard packs.
15 pcs. – contour cell blisters (2) – cardboard packs.
30 pcs. – contour cell blisters (1) – cardboard packs.
30 pcs. – jars (1) – cardboard packs.

Medixlife (Author)

View all posts Profile link